Key Takeaways
- FDA approval creates availability; access determines whether patients can receive therapy.
- Payer evidence often takes significant time to develop—waiting until launch leaves few options.
- The patient journey continues after the prescription through benefit verification, authorization and specialty pharmacy.
- Coverage creates opportunity; commercial execution still must translate opportunity into treatment initiation.
FDA approval is a defining milestone. Commercially, however, approval answers only one question: Can the product be made available?
It does not answer whether patients can realistically receive it. That distinction makes early Market Access planning essential.
PharmaKonsult approaches this as commercial market access strategy—integrating access into commercialization leadership, not replacing specialist payer analytics.
Evidence Decisions Occur Before Launch
Payer decisions may depend upon evidence that takes significant time to develop.
Leadership should consider health economic evidence, burden of illness, healthcare utilization, patient journey, budget impact, comparative value and quality of life.
Waiting until launch to identify these gaps may leave few options.
Understand the Access Journey
The patient journey does not end with the prescription. For many specialty therapies, treatment may require diagnosis, specialist evaluation, treatment decision, benefit verification, prior authorization, specialty pharmacy coordination, patient support and treatment initiation.
Failure at any stage can prevent therapy from reaching the patient.
Align Commercial and Access Strategy
Market Access should not operate independently from broader commercialization.
If reimbursement creates barriers, commercial field teams need to understand them. If institutions require specific evidence, Medical Affairs should understand it. If prior authorization becomes complex, patient services must be prepared. If distribution creates friction, commercial strategy must account for it.
That integration is a core part of biotech commercialization consulting and launch readiness work.
Coverage Is Not Commercial Success
One of the most important distinctions in pharmaceutical commercialization is the difference between coverage and execution.
A favorable reimbursement environment creates an opportunity. Commercial organizations still need to translate that opportunity into physician confidence and patient access.
Begin With the Future Patient
Ask a simple question:
What must happen between FDA approval and a patient successfully beginning therapy?
Map every step. Identify every potential failure point. Then begin solving those problems before launch.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
